These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 8164250

  • 1. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
    Fournié-Zaluski MC, Coric P, Turcaud S, Rousselet N, Gonzalez W, Barbe B, Pham I, Jullian N, Michel JB, Roques BP.
    J Med Chem; 1994 Apr 15; 37(8):1070-83. PubMed ID: 8164250
    [Abstract] [Full Text] [Related]

  • 2. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.
    Fournié-Zaluski MC, Gonzalez W, Turcaud S, Pham I, Roques BP, Michel JB.
    Proc Natl Acad Sci U S A; 1994 Apr 26; 91(9):4072-6. PubMed ID: 8171037
    [Abstract] [Full Text] [Related]

  • 3. Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
    Coric P, Turcaud S, Meudal H, Roques BP, Fournie-Zaluski MC.
    J Med Chem; 1996 Mar 15; 39(6):1210-9. PubMed ID: 8632427
    [Abstract] [Full Text] [Related]

  • 4. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
    Gonzalez Vera W, Fournié-Zaluski MC, Pham I, Laboulandine I, Roques BP, Michel JB.
    J Pharmacol Exp Ther; 1995 Jan 15; 272(1):343-51. PubMed ID: 7815350
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.
    Fink CA, Carlson JE, McTaggart PA, Qiao Y, Webb R, Chatelain R, Jeng AY, Trapani AJ.
    J Med Chem; 1996 Aug 02; 39(16):3158-68. PubMed ID: 8759637
    [Abstract] [Full Text] [Related]

  • 7. Exploration of neutral endopeptidase active site by a series of new thiol-containing inhibitors.
    Gomez-Monterrey I, Turcaud S, Lucas E, Bruetschy L, Roques BP, Fournié-Zaluski MC.
    J Med Chem; 1993 Jan 08; 36(1):87-94. PubMed ID: 8421293
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Dual inhibition of converting enzyme and neutral endopeptidase: a research new way in the field of hypertension].
    Fournie-Zaluski MC.
    C R Seances Soc Biol Fil; 1992 Jan 08; 186(6):612-25. PubMed ID: 1339591
    [Abstract] [Full Text] [Related]

  • 10. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril.
    Gros C, Noël N, Souque A, Schwartz JC, Danvy D, Plaquevent JC, Duhamel L, Duhamel P, Lecomte JM, Bralet J.
    Proc Natl Acad Sci U S A; 1991 May 15; 88(10):4210-4. PubMed ID: 1851998
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.
    Farina NK, Johnston CI, Burrell LM.
    J Hypertens; 2000 Jun 15; 18(6):749-55. PubMed ID: 10872560
    [Abstract] [Full Text] [Related]

  • 14. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
    Pham I, Gonzalez W, el Amrani AI, Fournié-Zaluski MC, Philippe M, Laboulandine I, Roques BP, Michel JB.
    J Pharmacol Exp Ther; 1993 Jun 15; 265(3):1339-47. PubMed ID: 8389863
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors.
    Seymour AA, Asaad MM, Abboa-Offei BE, Smith PL, Rogers WL, Dorso CR.
    J Pharmacol Exp Ther; 1996 Feb 15; 276(2):708-13. PubMed ID: 8632340
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat.
    Arbin V, Claperon N, Fournié-Zaluski MC, Roques BP, Peyroux J.
    Br J Pharmacol; 2001 Jun 15; 133(4):495-502. PubMed ID: 11399666
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Characterization of a dual inhibitor of angiotensin I-converting enzyme and neutral endopeptidase.
    French JF, Flynn GA, Giroux EL, Mehdi S, Anderson B, Beach DC, Koehl JR, Dage RC.
    J Pharmacol Exp Ther; 1994 Jan 15; 268(1):180-6. PubMed ID: 8301555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.